Live
- PM Modi’s welfare schemes transform rural lives in Bokaro, residents share gratitude
- We will ensure Bangladeshi infiltrators are removed from Jharkhand: BJP's Gourav Vallabh
- Hezbollah fires five rockets at central, northern Israel: sources
- HM Amit Shah, Rajnath Singh to address several rallies in Jharkhand tomorrow
- Will not waste single day in getting back what we lost, Omar Abdullah tells Assembly
- PM Modi visits Advani's residence to wish him on birthday, shares special moment
- Sun-Dried Cotton to Be Taken to CCI Purchase Centers, Avoid Middlemen - Collector
- Survey Process Requires Public Cooperation - Collector Badavath Santosh
- Distribution of Maize Seeds to Farmers at Agricultural Research Center
- Education with Human Values Must be Provided to Students - Telangana State Higher Education Council Chairman Prof. V. Balakista Reddy
Biovet to invest Rs 200 crores for facility expansion
Biovet Private Limited, an animal vaccine maker, announced that it would invest Rs 200 crore as part of its expansion plans to meet the growing market demand for the vaccine which tackles Foot & Mouth Disease (FMD) and Brucellosis in animals.
Hyderabad: Biovet Private Limited, an animal vaccine maker, announced that it would invest Rs 200 crore as part of its expansion plans to meet the growing market demand for the vaccine which tackles Foot & Mouth Disease (FMD) and Brucellosis in animals.
Biovet informed that it commenced the work towards expanding the FMD vaccine manufacturing facility in Malur, Karnataka.
Krishna Ella, Founder, Biovet, said: "Expansion of our FMD vaccine facilities to deliver 200 million doses is an important step to increase our contribution to meet the shortage of this vaccine in the country."
The company based in Bengaluru will construct a new Brucella Vaccine Production facility at the Malur site to produce 100 million doses.
The vaccine maker said that according to estimates, India's FMD control programme requires 1,000 million doses every year, whereas the current production capacity manufactured in the country is only around 500 million doses.
There is an unmet need for 500 million doses, and Biovet aims to fulfil this gap.
